**Supplementary Table S1**

**Table S1**. Anticancer therapies associated with CV complications or toxicities

|  |  |  |  |
| --- | --- | --- | --- |
| **Anticancer agents** | **Cancer use** | **Type of cardiotoxicity** | **Frequency** |
| **Anthracyclines** |
| Doxorubicin [1, 2] | Breast, sarcoma,  lung, bladder,  gastric,  prostate,  leukaemia,  lymphoma,  others | HFLVDArrhythmia | Common |
| Epirubicin [3] | Breast,  oesophageal,  gastric | HFLVDArrhythmia | Common |
| **Alkylating agents** |
| Cyclophosphamide [4] | Breast,  lymphoma,  myeloma,  sarcoma, SCT | HFLVDMyopericarditisArrhythmia | Uncommon |
| Ifosfamide [5, 6] | Testicular,  sarcoma,  lymphoma | HFLVDMyopericarditisArrhythmia | Common |
| Cisplatin [7, 8] | Lung, bladder,  testicular,  breast,  oesophageal,  head and  neck | ArrhythmiaIschaemiaVTEHTN | UncommonCommon |
| Melphalan [9, 10] | MM, ovarian,  neuroblastoma,  SCT | ArrhythmiaLVD | CommonRare |
| **Antimetabolites** |
| Fluorouracil [11-15] | Colon, pancreatic,  breast, head and  neck | Coronary vasospasmIschaemiaArrhythmiaLVDMyocarditis | CommonUncommonRare |
| Capecitabine [16, 17] | Breast, colon,  gastric,  pancreatic | Coronary vasospasmIschaemiaArrhythmiaLVD | CommonUncommon |
| Fludarabine [18, 19] | Lymphoma,  leukaemia, SCT | AnginaIschaemiaArrhythmiaLVD | Uncommon |
| Decitabine [20] | MDS | HFLVD | Uncommon |
| **Antimicrotubule agents** |
| Docetaxel [21, 22] | Breast, lung, prostate,  gastric, head and  neck | HFLVDArrhythmia | Uncommon |
| Paclitaxel [23-25] | Breast, ovarian, lung,  sarcoma, bladder,  cervical, gastric,  oesophageal,  head and neck | IschaemiaBradyarrhythmia | Rare |
| Vinblastine [26-28] | Lymphoma, testicular,  lung, melanoma | IschaemiaArrhythmia | Rare |
| **Monoclonal antibodies** |
| Rituximab [29]Ofatumumab [30]Alemtuzumab [31] | Lymphoma,  leukaemia | Hypotension  (infusion  reaction)HTNLVDHF | CommonUncommon |
| **Monoclonal antibodies (HER2)** |
| Bevacizumab [32-34] | Colorectal, cervical,  glioblastoma,  ovarian, renal,  endometrial,  sarcoma, breast | HTNVTEATEMyocardial ischaemiaLVD | CommonUncommon |
| Pertuzumab [35] | Breast | HFLVD | Uncommon |
| Trastuzumab [36-38]  | Breast, gastric,  gastroesophageal | HFLVD | Common |
| **Small-molecule TKIs** |
| Dabrafenib [39-41] | Melanoma | QT prolongationHFLVDVTE | CommonRarea |
| Dasatinib [42, 43] | Leukaemia, GIST | HFLVDQT prolongationPulmonary HTN | UncommonRare |
| Lapatinib [44-46] | Breast | HFLVD | Uncommon |
| Pazopanib [47, 48] | Renal, sarcoma,  thyroid | HTNBradyarrhythmiaHFLVDVTEQT prolongationischaemia | CommonUncommon |
| Ponatinib [42, 49, 50] | Leukaemia | HFLVDHTNIschaemiaATEVTE | Common |
| Sorafenib [51-54] | Hepatocellular, renal,  thyroid | HTNHFLVDIschaemia | Common |
| Trametinib [40, 55, 56] | Melanoma | HFLVDBradyarrhythmiaQT prolongationVTEHTN | Common |
| Sunitinib [34, 48, 57] | Renal, thyroid,  sarcoma, GIST,  PNET | HTNHFLVDVTEATE | CommonUncommon |
| Axitinib [58] | Renal | HTNVTE | CommonUncommon |
| Nilotinib [42, 59] | Leukaemia | IschaemiaVTEATEQT prolongationAtherosclerosisHyperglycaemia/diabetes | Uncommon |
| Ibrutinib [60, 61] | Lymphoma | Atrial fibrillationHTNBleedingVentricular arrhythmia | CommonRare |
| Ramucirumab [62, 63] | Colorectal, gastric,  lung | HTNATEVTE | CommonUncommon |
| Regorafenib [63, 64] | Colorectal, GIST | HTNIschaemia | CommonRare |
| Imatinib [42, 65] | Leukaemia, GIST,  MDS, melanoma,  mastocytosis,  sarcoma | LVDHFOedema | RareCommon |
| Vandetanib [63, 66] | Thyroid | HTNQT prolongationHFLVD | CommonRare |
| Ziv-aflibercept [63, 67] | Colorectal cancer | HTNQT prolongationVTEATE | CommonUncommon |
| Cabozantinib [63, 68] | Thyroid, renal | HTNVTE | Common |
| Erlotinib [69-71]Cetuximab [72, 73] | Lung, pancreatic,  colorectal | VTEIschaemiaSCD | CommonRare |
| Ceritinib [74] | Lung | QT prolongationBradyarrhythmia | Uncommon |
| Crizotinib [75] | Lung | BradyarrhythmiabQT prolongation | Uncommon |
| Vemurafenib [41, 76] | Melanoma | HTNQT prolongationArrhythmiaVTE | UncommonRare |
| **Immune checkpoint inhibitors** |
| NivolumabIpilimumabPembrolizumab[77-79] | Melanoma, lung,  kidney, bladder,  head and neck,  lymphoma | MyocarditisArrhythmiaLVDSCDVasculitisPericarditis | Uncommon |
| **Protease inhibitors** |
| Bortezomib [80, 81] | MM, MCL | HFLVDVTEcHTN | UncommonCommon |
| Carfilzomib [82-84] | MM | HFLVDVTEHTNACSPulmonary HTN | CommonUncommon |
| **mTOR inhibitors** |
| Everolimus [85] | Breast, pancreas | HTNVTE | CommonUncommon |
| Temsirolimus [86] | Renal | HTN | Common |
| **IMiDs** |
| Lenalidomide [87]Thalidomide [88]Pomalidomide [89] | MM | VTEBradycardia | CommonUncommon |
| **Histone deacetylase inhibitors** |
| Vorinostat [90, 91]Belinostat [92] | Lymphoma | QT prolongationVTE | CommonUncommon |
| **Endocrine therapy** |
| Selective ER modulators * Tamoxifen [93]
* Toremifene [94]
 | Breast cancer | VTEQT prolongation | Common |
| AIs * Anastrozole [95]
* Letrozole [96]
* Exemestane [97]
 | Breast cancer | VTEHTNHyperlipidaemia | Common |
| LHRH agonists * Goserelin [98]
* Leuprolide [99]
 | Breast, endometrial, prostate | IschaemiaVTECVAHFLVDQT prolongation | Uncommon |
| Antiandrogens* Flutamide [100]
* Bicalutamide [101]
* Nilutamide [102]
 | Prostate cancer | ArrhythmiaATEVTEHFLVDQT prolongationHTN | UncommonCommon |
| **Chimeric antigen receptor (CAR) T Cell Therapy** |
| Tisagenlecleucel [103]Axicabtagene ciloleucel [104] | B cell acute lymphoblastic leukaemia (refractory or relapse)Large B cell lymphoma (refractory or relapse) | TachycardiaArrhythmiaHypotensionHTNHFCapillary leak syndromeMI (unrelated to CAD, likely due to antigen mimicry)Cardiac arrest | CommonUncommon |
| **Miscellaneous** |
| Ribociclib [105] | Breast cancer | QT prolongation | Uncommond |
| Bleomycin [106-108] | SCC, melanoma, sarcoma, testicular, lymphoma | IschaemiaPericarditisCVA | Rare |
| Tretinoin [109, 110] | Leukaemia | HFLVD | Common |
| Arsenic trioxide [111, 112] | Leukaemia | QT prolongationHeart block | CommonRare |

aThese side effects are common when used in combination with trametinib.

bPer package insert, it was reported in 5 % of cases but was of low grade.

cVTE is common with bortezomib if used in combination with IMiDs.

dClinical trials excluded patients on other QT prolonging medications. In the clinical setting, this might be more common due to concomitant use of other QT-prolonging medications.

The frequency of toxicity was graded as common ≥5% incidence, uncommon 1%–5% incidence or rare <1% incidence in clinical trials or observational studies.

ACS, acute coronary syndrome; AI, aromatase inhibitor; ATE, arterial thromboembolism; CAD, coronary artery disease; CV, cardiovascular; CVA, cerebrovascular accident; ER, oestrogen receptor; GIST, gastrointestinal stromal tumour; HER2, human epidermal growth factor receptor 2; HF, heart failure; HTN, hypertension; IMiD, immunomodulatory drug; LHRH, luteinizing hormone-releasing hormone; LVD, left ventricular dysfunction; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MI, myocardial infarction; MM, multiple myeloma; mTOR, mammalian target of rapamycin; PNET, pancreatic neuroendocrine tumour; QT, corrected QT interval (preferably by Fridericia’s formula); SCC, squamous cell cancer; SCD, sudden cardiac death; SCT, stem cell transplant; TKI, tyrosine kinase inhibitor; VTE, venous thromboembolism.

References

1. Doxorubicin Hydrochloride for Injection, USP [package insert]. Phramacia & Upjohn Company, Division of Pfizer Inc, NY, NY 10017. 2010.

2. Murbraech K, Wethal T, Smeland KB et al. Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study. JACC Cardiovasc Imaging 2016; 9: 230-239.

3. Epirubicin Hydrochloride for Injection [package insert]. Mayne Pharma Limited Mulgrave, VIC 3170, Australia. 2006.

4. Cyclophosphamide [package insert]. Baxter Healthcare Corporation Deerfield, IL 60015 USA. 2013.

5. Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31-36.

6. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.

7. Cisplatin (Platinol) [package insert]. Bristol-Myers Squibb Company Princeton, New Jersey 08543 USA. 2010.

8. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998; 160: 2021-2024.

9. Yanamandra U, Gupta S, Khadwal A, Malhotra P. Melphalan-induced cardiotoxicity: ventricular arrhythmias. BMJ Case Rep 2016; 2016.

10. Melphalan (Alkeran) [package insert]. GlaxoSmithKline, Research Triangle Park, NC 27709.

11. Fluorouracil [package insert]. Spectrum Pharmaceuticals, Inc. Irvine, CA 92618. 2016.

12. Meyer CC, Calis KA, Burke LB et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17: 729-736.

13. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-2247.

14. Sasson Z, Morgan CD, Wang B et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 1994; 10: 861-864.

15. Killu A, Madhavan M, Prasad K, Prasad A. 5-fluorouracil induced pericarditis. BMJ Case Rep 2011; 2011.

16. Van Cutsem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002; 13: 484-485.

17. Capecitabine (Xeloda) [package insert]. Genentech USA, Inc. A Member of the Roche Group. 1 DNA Way, South San Francisco CA. 2015.

18. Fludarabine (Fludara) [package insert]. Berlex, Montville, NJ 07045. 2003.

19. Hussein MA, Gundacker H, Head DR et al. Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706. Leukemia 2005; 19: 1880-1886.

20. Decitabine (Dacogen) [package insert]. MGI PHARMA, INC., Bloomington, MN 55437. 2006.

21. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.

22. Docetaxel [package insert]. Sandoz, Princeton NJ 08540. 2012.

23. Paclitaxel (Taxol) [package insert]. Bristol-Myers Squibb Company, Princeton, NJ 08543 USA 2011.

24. Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704-1712.

25. Arbuck SG, Strauss H, Rowinsky E et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993; 117-130.

26. Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep 1986; 70: 690-691.

27. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19: 253-256.

28. Vinblastine [package insert]. Bedford Laboratories, Bedford, Ohio 44146. 2012.

29. Rituximab [package insert]. Genentech, Inc. A Member of the Roche Group,1 DNA Way, South San Francisco, CA. 2010.

30. Ofatumumab (Arzerra) [package insert]. GlaxoSmithKline Research Triangle Park, NC 27709. 2009.

31. Alemtuzumab (Campath) [package insert]. Millennium and ILEX Partners, LP Cambridge, MA 02142. 2001.

32. Bevacizumab (Avastin) [package insert]. Genentech, Inc. 1 DNA Way, South San Francisco, CA. 2009.

33. Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008; 118: 84-95.

34. Li W, Croce K, Steensma DP et al. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J Am Coll Cardiol 2015; 66: 1160-1178.

35. Pertuzumab (Perjeta) [package insert]. Genentech, Inc. A Member of the Roche Group, 1 DNA Way, South San Francisco, CA. 2012.

36. Trastuzuman (Herceptin) [package insert]. Genentech, Inc. 1 DNA Way, South San Francisco, CA. 2010.

37. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.

38. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-3865.

39. Dabrafenib (Tafinlar) [package insert]. GlaxoSmithKline Research Triangle Park, NC 27709. 2014.

40. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.

41. Bronte E, Bronte G, Novo G et al. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget 2015; 6: 35589-35601.

42. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 2015; 33: 4210-4218.

43. Dasatinib (Sprycel) [package insert]. Bristol-Myers Squibb Company, Princeton, NJ 08543 USA. 2010.

44. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-686.

45. Battisti NML, Tong D, Ring A, Smith I. Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience. Breast Cancer Res Treat 2019.

46. Lapatinib (Tykerb) [package insert]. GlaxoSmithKline, Research Triangle Park, NC 27709.

47. Pazopanib (Votrient) [package insert]. GlaxoSmithKline, Research Triangle Park, NC 27709. 2009.

48. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-731.

49. Ponatinib (Iclusig) [package insert]. ARIAD Pharmaceuticals, Inc. 26 Landsdowne Street, Cambridge, MA, USA. 2012.

50. Cortes JE, Kim DW, Pinilla-Ibarz J et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-1796.

51. Sudasena D, Balanescu DV, Donisan T et al. Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. Cardiovasc Toxicol 2019; 19: 382-387.

52. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol 2014; 10: 1981-1992.

53. Pantaleo MA, Mandrioli A, Saponara M et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012; 12: 231.

54. Sorafenib (Nexavar) [package insert]. Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ 07470, USA. . 2010.

55. Trametinib (Mekinist) [package insert]. GlaxoSmithKline, Research Triangle Park, NC 27709, USA. 2014.

56. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.

57. Sunitinib (Sutent) [package insert]. Pfizer Labs, Division of Pfizer Inc, New York, NY 10017, USA. 2011.

58. Axitinib (Inlyta) [package insert]. Pfizer Labs, Division of Pfizer Inc, New York, NY 10017, USA. 2012.

59. Nilotinib (Tasigna) [package insert]. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936, USA. 2010.

60. Ibrutinib (Ibruvica) [package insert]. Pharmacyclics, Inc. Sunnyvale, CA USA 94085

 2015.

61. Ganatra S, Majithia A, Shah S. Challenges in ibrutinib associated atrial fibrillation. J Am Coll Cardiol 2017; 11: 2308.

62. Ramucirumab (Cyramza) [package insert]. Eli Lilly and Company, Indianapolis, IN 46285, USA. 2014.

63. Santoni M, Guerra F, Conti A et al. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. Cancer Treat Rev 2017; 59: 123-131.

64. Regorafenib (Stivarga) [package insert]. Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ 07470, USA. 2012.

65. Imatinib [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2001.

66. Vandetanib (Caprelsa) [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA 2014.

67. Ziv-aflibercept (Zaltrap) [package insert]. Sanofi-aventis U.S. LLC, Bridgewater, NJ 08807, USA. 2012.

68. Cabozantinib (Cambometyx) [package insert]. Exelixis, Inc. South San Francisco, CA 94080 USA. 2016.

69. Mak IT, Kramer JH, Chmielinska JJ et al. EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade. J Cardiovasc Pharmacol 2015; 65: 54-61.

70. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.

71. Erlotinib (Tarceva) [package insert]. OSI Pharmaceuticals Inc., Melville, NY 11747, USA. . 2010.

72. Cetuximab (Erbitux) [package insert]. Bristol-Myers Squibb Company, Princeton, NJ 08543 USA. 2012.

73. Tang XM, Chen H, Liu Y et al. The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Medicine (Baltimore) 2017; 96: e5946.

74. Ceritinib (Zykadia) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2017.

75. Crizotinib (Xalkori) [package insert]. Pfizer Labs, Division of Pfizer Inc, New York, NY 10017, USA

 2012.

76. Vemurafenib (Zelboraf) [package insert]. Genentech USA, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080, USA. 2016.

77. Johnson DB, Balko JM, Compton ML et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016; 375: 1749-1755.

78. Mahmood SS, Fradely MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am College Cardiol 2018; In Press.

79. Ganatra S, Neilan TG. Immune Checkpoint Inhibitor Associated Myocarditis. Oncologist 2018; In Press.

80. Bortezomib [package insert]. Millennium Pharmaceuticals Inc., 40 Landsdowne Street, Cambridge, MA 02139, USA. 2014.

81. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk 2011; 11: 228-236.

82. Carfilzomib [package insert]. Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320, USA. 2016.

83. Siegel D, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753-1761.

84. Stewart AK, Rajkumar SV, Dimopoulos MA et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142-152.

85. Everolimus [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA 2010.

86. Temsirolimus (Torisel) [package insert]. Wyeth Pharmaceuticals Inc, Philadelphia, PA 19101, USA. 2015.

87. Lenalidomide (Revlimid) [package insert]. Celgene Corporation, Summit, NJ 07901, USA. 2017.

88. Thalidomide [package insert]. In. Summit, NJ 07901, USA: Celgene Corporation 2014.

89. Pomalidomide [package insert]. Celgene Corporation, Summit, NJ 07901, USA. 2013.

90. Mann BS, Johnson JR, Cohen MH et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-1252.

91. Vorinostat (Zolinza) [package insert]. MERCK & CO., INC. Whitehouse Station, NJ 08889, USA. 2006.

92. Belinostat (Beleodaq) [package insert]. Spectrum Pharmaceuticals, Inc., Irvine, CA 92618, USA. 2014.

93. Tamoxifen [package insert]. In. Wilmington, Delaware 19850, USA: AstraZeneca Pharmaceuticals LP 2004.

94. Toremifene [package insert]. In. Mephis, TN 38103, USA: GTx, Inc. 2011.

95. Anastrozole (Arimidex) [package insert]. In. Wilmington, DE 19850, USA: AstraZeneca Pharmaceuticals LP 2009.

96. Letrozole (femara) [package insert]. In. East Hanover, New Jersey, 07936, USA: Novartis Pharmaceuticals Corporation 2014.

97. Exemestane (Aromasin) [package insert]. In. NY 10017, USA: Pharmacia & Upjohn Co., Division of Pfizer Inc, NY 2011.

98. Goserelin (Zoladex) [package insert]. In. Wilmington, DE 19850, USA: AstraZeneca Pharmaceuticals LP 2015.

99. Leuprolide (Lupron) [package insert]. In. North Chicago, IL 60064, USA: AbbVie Inc. 2014.

100. Flutamide [package insert]. Schering Corp., Kenilworth, NJ 07033, USA. 2001.

101. Bicalutamide [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA. 2015.

102. Nilutamide [package insert]. ANI Pharmaceuticals, Inc., Baudette, MN 56623, USA. 2015.

103. Tisagenlecleucel (Kymriah) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2017.

104. Axicabtagene ciloleucel (Yescarta) [package insert]. Kite Pharma, Inc., Santa Monica, CA 90404, USA. 2017.

105. Ribociclib (Kisqali) [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA. 2017.

106. Didagelos M, Boutis A, Diamantopoulos N et al. Bleomycin cardiotoxicity during chemotherapy for an ovarian germ cell tumor. Hippokratia 2013; 17: 187-188.

107. Vogelzang NJ, Frenning DH, Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 1980; 64: 1159-1160.

108. Bleomycin (Blenoxane) [package insert]. Mead Johnson Oncology Products, A Bristol-Myers Subsid Co., Princeton, NJ 08543, USA.

109. Tretinoin [package insert]. Roche Laboratories Inc., 340 Kingsland Street, Nutley, NJ 07110, USA. 2004.

110. Simbre IV, Adams MJ, Deshpande SS et al. Cardiomyopathy Caused by Antineoplastic Therapies. Curr Treat Options Cardiovasc Med 2001; 3: 493-505.

111. Arsenic trioxide (Trisenox) [package insert]. Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, USA. 2015.

112. Kathirgamanathan K, Angaran P, Lazo-Langner A, Gula LJ. Cardiac conduction block at multiple levels caused by arsenic trioxide therapy. Can J Cardiol 2013; 29: 130 e135-136.